Genmab A/S (NASDAQ:GMAB) Price Target Raised to $47.00 at BTIG Research

Genmab A/S (NASDAQ:GMAB) had its target price boosted by BTIG Research from $46.00 to $47.00 in a research report sent to investors on Thursday, Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages also recently weighed in on GMAB. HC Wainwright reaffirmed a buy rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday. Morgan Stanley reaffirmed an underweight rating on shares of Genmab A/S in a research report on Tuesday, March 26th. Finally, Truist Financial increased their price target on Genmab A/S from $50.00 to $53.00 and gave the stock a buy rating in a research report on Tuesday, June 4th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Hold and an average price target of $49.50.

Genmab A/S Price Performance

NASDAQ GMAB opened at $25.58 on Thursday. The stock’s fifty day moving average price is $28.08 and its 200 day moving average price is $29.18. Genmab A/S has a 1 year low of $25.38 and a 1 year high of $42.72. The company has a market cap of $16.92 billion, a price-to-earnings ratio of 21.32, a PEG ratio of 0.93 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share for the quarter, hitting the consensus estimate of $0.16. The company had revenue of $603.30 million for the quarter, compared to the consensus estimate of $594.23 million. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. Research analysts expect that Genmab A/S will post 1.11 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors have recently modified their holdings of GMAB. HighTower Advisors LLC lifted its stake in Genmab A/S by 30.7% in the 3rd quarter. HighTower Advisors LLC now owns 9,009 shares of the company’s stock valued at $322,000 after buying an additional 2,114 shares in the last quarter. Citigroup Inc. lifted its stake in Genmab A/S by 148.2% in the 3rd quarter. Citigroup Inc. now owns 21,545 shares of the company’s stock valued at $760,000 after buying an additional 12,863 shares in the last quarter. FMR LLC lifted its stake in Genmab A/S by 6.3% in the 3rd quarter. FMR LLC now owns 422,437 shares of the company’s stock valued at $14,899,000 after buying an additional 24,936 shares in the last quarter. Mariner LLC lifted its stake in Genmab A/S by 183.4% in the 3rd quarter. Mariner LLC now owns 49,018 shares of the company’s stock valued at $1,729,000 after buying an additional 31,720 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in Genmab A/S by 83.3% in the 3rd quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock valued at $19,717,000 after buying an additional 254,042 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.